Rumors, have you seen today's press. Tricom have been moving them out for months.
IMO this stock is well and truly undersold.
It has a compound in ph3 that if successful will be the new standard of care for post surgery liver cancer patients worldwide.
Based on the companies’ stated addressable market of 65,000, post surgery cases a year at $40k a go and even with a 50% penetration that's over $1B USD in sales a year.
Remember that 65% of all compounds that enter ph3 end up on the market. Also remember in the ph2 trail the compound showed a 76% increase in DFS (the ph3 end point is 40%) this gives PI-88 a much better chance of being in the 65% that make it to market.
As for timing, recent Avastin and Nexavar trials were halted (because it became unethical to exclude the placebo arm from access to the drug) within an average of 20 months. Both these trials were in diseases that already have treatment options available to patients. Post surgery liver patients have no options, they can either wait for the cancer to reappear (average of 50% in 12 months) or go on the PGL trial. Based on this you could concluded that enrolment in the ph3 trail would be relative quick. Thought I know it’s been a little late starting I would expect it to pick up in the coming months. This leads me to believe we could see a rollover in this trial with a 20 month period if not sooner.
PGL Price at posting:
0.0¢ Sentiment: Buy Disclosure: Held
